– USA, TX – Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Reid M. Huber, Ph.D. to its Board of Directors.
Dr. Huber has over 16 years of experience in pharmaceutical research and clinical development, in both senior leadership and scientific research positions. He currently serves as Executive Vice President and Chief Scientific Officer at Incyte Corporation where he leads drug discovery research primarily in the area of hematology/oncology.
“Dr. Huber has an impressive track record of leading drug discovery research, and a depth of knowledge and understanding of immuno-oncology that is central to several of Bellicum’s clinical programs,” commented Tom Farrell, CEO of Bellicum Pharmaceuticals. “We look forward to the unique perspective Reid can bring to Bellicum as we advance our novel cell therapy product candidates.”
Added Dr. Huber, “I am eager to work closely with fellow Bellicum directors and the management team in helping to achieve the full potential of the Company’s promising controlled-cell therapies.”
Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a founding member of the team that started drug discovery at Incyte Corporation in 2002. He received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University, and later trained at the National Institutes of Health.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
